LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Globe Newswire (Thu, 6-Aug 5:15 PM ET)
Artegraft Drives Record Growth as LeMaitre Delivers Strong Margins and Expands Global Reach
Market Chameleon (Wed, 5-Aug 4:05 AM ET)
LeMaitre Q2 2026 Financial Results
Globe Newswire (Tue, 4-Aug 4:05 PM ET)
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
Globe Newswire (Tue, 14-Jul 5:43 PM ET)
LeMaitre to Participate at Upcoming Investor Conferences in June
Globe Newswire (Wed, 20-May 4:25 PM ET)
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Lemaitre Vascular trades on the NASDAQ stock market under the symbol LMAT.
As of August 17, 2026, LMAT stock price declined to $82.34 with 145,811 million shares trading.
LMAT has a beta of -0.20, meaning it tends to be less sensitive to market movements. LMAT has a correlation of 0.00 to the broad based SPY ETF.
LMAT has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Lemaitre Vascular reported $70 million in Revenue and $.74 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.07.
In the last 3 years, LMAT traded as high as $118.01 and as low as $44.27.
The top ETF exchange traded funds that LMAT belongs to (by Net Assets): IJR, SDVY, VTI, IWM, VXF.
LMAT has underperformed the market in the last year with a price return of -13.1% while the SPY ETF gained +21.0%. LMAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.0% and -18.7%, respectively, while the SPY returned +3.5% and +3.4%, respectively.
LMAT support price is $80.56 and resistance is $84.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LMAT shares will trade within this expected range on the day.